Israeli Study Reveals Hyperimmune Plasma as Potential Breakthrough Treatment for West Nile Virus
A clinical trial conducted at Sheba Medical Center in Israel has demonstrated promising results for a novel treatment approach to West Nile Virus (WNV). The study, published in NEJM Evidence, suggests that administering plasma rich in neutralizing antibodies can significantly reduce mortality and improve recovery in patients with severe WNV.
The Summer Crisis of 2024: An Unprecedented Outbreak
West Nile Fever is a viral disease transmitted to humans primarily through the bite of Culex mosquitoes that have previously infected birds. While most infections are mild or asymptomatic, approximately 1% of cases, particularly in individuals over 65 or those with compromised immune systems, can lead to severe neurological complications.
During the summer of 2024, Israel experienced an unusually large outbreak of WNV, with hospitals reporting a significant increase in severe cases. Prof. Gili Regev-Yochay, who led the study and heads the infection prevention and control unit at Sheba Medical Center, noted the severity of the situation, stating that patients experienced “devastating neurological deterioration” with symptoms including confusion, loss of consciousness, and paralysis.
Hyperimmune Plasma: A Novel Therapeutic Approach
Traditionally, treatment for severe WNV has been limited to supportive care, such as hydration, fever control, and mechanical ventilation. Recognizing the urgent require for a more targeted therapy, researchers at Sheba Medical Center explored the potential of hyperimmune plasma – plasma collected from donors with high levels of neutralizing antibodies against the virus.
The team identified “super donors” – individuals with exceptionally high concentrations of these antibodies – and collected their plasma for use in a randomized, double-blind Phase 2 clinical trial. Critically ill patients received either the hyperimmune plasma or standard plasma (without the high antibody concentration), with neither patients nor physicians aware of the treatment assignment.
Clinical Results: Dramatic Improvement in Outcomes
The results of the trial, published in NEJM Evidence, revealed a substantial difference in outcomes between the two groups:
- Mortality Reduction: The mortality rate in the group receiving hyperimmune plasma was 9% (2 deaths), compared to 33% (a third of patients) in the control group.
- Complete Survival with High Antibody Levels: Patients who received plasma with the highest concentrations of neutralizing antibodies had a 100% survival rate.
- Cognitive and Functional Recovery: Patients treated with hyperimmune plasma demonstrated significantly improved cognitive function, as measured by the Mental State Examination, and greater motor independence in daily activities, assessed using the Barthel index.
The study included 34 critically ill patients, providing a statistically significant sample size to support the findings.
From Treatment to Prevention: The Future of Monoclonal Antibodies
Building on the success of the hyperimmune plasma trial, Sheba Medical Center is now focused on developing a synthetic monoclonal antibody against WNV. Plasma from human donors is a limited resource, making a scalable, laboratory-produced antibody a more sustainable solution.
Prof. Regev-Yochay envisions a future where a single injection of this synthetic antibody could provide temporary passive immunization, protecting vulnerable populations – such as those over 70 or individuals with cancer – during peak mosquito season.
Global Implications of Israeli Innovation
This research, published by Israeli scientists in NEJM Evidence, has global implications. Climate change is expanding mosquito habitats, increasing the risk of WNV outbreaks in fresh regions, including parts of Europe and North America.
The success of this Israeli study highlights the country’s ability to translate clinical needs into innovative biotechnological solutions, offering a potential new weapon in the fight against this growing global health threat.